Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nim811 + peginterferon + ribavirin
- Development stage
- Discontinued
- Lead developer
- Novartis
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Administration
- Oral, Subcutaneous
01
Overview
NIM811 + peginterferon + ribavirin is an investigational combination therapy for chronic hepatitis C virus (HCV) infection, particularly genotype 1. NIM811 (SDZ 211-811) is a non-immunosuppressive cyclophilin inhibitor developed by Novartis. It is a small molecule cyclosporine derivative that targets host cyclophilins, specifically cyclophilin A (PPIA), which are cellular peptidyl-prolyl isomerases required for the formation of the HCV replication complex. Unlike cyclosporine A, NIM811 lacks calcineurin-mediated immunosuppressive activity. The combination includes peginterferon alpha (a pegylated cytokine) and ribavirin (a nucleoside analog), which were the standard-of-care backbone for HCV treatment. The triple combination was studied to enhance antiviral efficacy and suppress the emergence of drug resistance in HCV patients, especially those who had relapsed on previous interferon-based therapies.
- Other names
- MeIle4-cyclosporinMeIle-4-cyclosporinMeIle 4-cyclosporin[MeIle]4-cyclosporin
02
Targets
IMPDH (Inosine-5'-monophosphate dehydrogenase 1)IFNAR (Immune system modulation via type I interferon receptor)PPIB (Cyclophilin B)IFNAR1 (Interferon alpha/beta receptor 1)PPIA (Peptidyl-prolyl cis-trans isomerase A)
Beyond the preview
Go deeper on nim811 + peginterferon + ribavirin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nim811 + peginterferon + ribavirin.